title: Central venous catheterization in pediatric patients affected by hematological malignancies.
abstract: The objective of this retrospective study was to evaluate the significance and complications of percutaneous central venous catheterization in pediatric patients affected by hematologic malignancies. One hundred and fifty-eight central venous catheters were inserted in 125 pediatric patients (male/female 67/58; median age: 4 years; range 10 m - 6 y.) affected by hematological malignancies. Venous access was obtained by means of a tunnelled silicone rubber Groshong catheter inserted percutaneously in the subclavian vein (91.1%), the internal jugular vein or in the femoral vein. The medial duration of catheterization was 231.8 days (range 8-1014 days). The total number of catheter days was 33,792 (92.6 years). There were no complications related to catheter insertion. Only one patient developed significant post-operative bleeding. One hundred and nine catheters (68.9%) were removed when they were no longer needed and 49 (31.1%) were removed due to complications: 6 catheter occlusions (12.2%), 7 were accidentally withdrawn (14.3%), 3 for local infections (6.1%) and 33 for catheter-related infection (67.3%). A Groshong catheter seems to provide good access to the blood stream for a long period of time with a low incidence of complications in children with acute hematological malignancies.
authors.affiliation: Institute of Anesthesia and Intensive Care, University of Rome, La Sapienza, Italy.
authors.forename: A A
authors.initials: AA
authors.lastname: Cogliati
authors.forename: D
authors.initials: D
authors.lastname: Dell'Utri
authors.forename: A
authors.initials: A
authors.lastname: Picardi
authors.forename: A M
authors.initials: AM
authors.lastname: Testi
authors.forename: A
authors.initials: A
authors.lastname: Micozzi
authors.forename: E
authors.initials: E
authors.lastname: Pasotti
authors.forename: G
authors.initials: G
authors.lastname: Rosa
mesh_terms: D000208:Acute Disease; D000970:Antineoplastic Agents / Q000008:administration & dosage; D016470:Bacteremia / Q000453:epidemiology / Q000209:etiology; D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000295:instrumentation / Q000706:statistics & numerical data; D002648:Child; D002675:Child, Preschool; D005260:Female; D016469:Fungemia / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D007223:Infant; D007938:Leukemia / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D009436:Neural Tube Defects / Q000628:therapy; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents